Immunomodulatory effects of Interleukin 2 in the circulation of melanoma patients and the added impact of VEGF inhibition with Ziv-aflibercept

被引：0
|
作者：
Khunger, Arjun [1 ]
Sarikonda, Ghanashyam [2 ]
Frankel, Paul [3 ]
Tsau, Jenn [2 ]
Alfonso, Zeni [2 ]
Gao, Jane [2 ]
Pahuja, Anil [2 ]
Vaupel, Christine [2 ]
Dakappagari, Naveen [2 ]
Tangri, Shabnam [2 ]
Tarhini, Ahmad [4 ,5 ]
机构：
[1] Mem Hosp West, Pembroke Pines, FL USA
[2] Navigate BioPharma Serv Inc, Carlsbad, CA USA
[3] City Hope Natl Med Ctr, Duarte, CA USA
[4] Emory Univ, Atlanta, GA 30322 USA
[5] Winship Comprehens Canc Ctr, Atlanta, GA USA
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2019年 / 7卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P13
引用
收藏
页数：2
相关论文
共 50 条
  • [31] INVITRO INHIBITION OF INTERLEUKIN-2 PRODUCTION BY PERIPHERAL-BLOOD LYMPHOCYTES FROM STAGE-III MELANOMA PATIENTS BY PROSTAGLANDIN-E2 - ENHANCEMENT OF LYMPHOCYTE-PROLIFERATION BY EXOGENOUS INTERLEUKIN-2 PLUS INDOMETHACIN
    MURRAY, JL
    DOWD, J
    HERSH, EM
    JOURNAL OF BIOLOGICAL RESPONSE MODIFIERS, 1986, 5 (01): : 12 - 19
  • [32] Cigarette smoke disrupts VEGF165-VEGFR-2 receptor signaling complex in rat lungs and patients with COPD:: morphological impact of VEGFR-2 inhibition
    Marwick, JA
    Stevenson, CS
    Giddings, J
    MacNee, W
    Butler, K
    Rahman, I
    Kirkham, PA
    AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, 2006, 290 (05) : L897 - L908
  • [33] Impact of Aspirin Dosing on the Effects of P2Y12 Inhibition in Patients with Acute Coronary Syndromes
    Mark R. Thomas
    Robert F. Storey
    Journal of Cardiovascular Translational Research, 2014, 7 : 19 - 28
  • [34] Impact of Aspirin Dosing on the Effects of P2Y12 Inhibition in Patients with Acute Coronary Syndromes
    Thomas, Mark R.
    Storey, Robert F.
    JOURNAL OF CARDIOVASCULAR TRANSLATIONAL RESEARCH, 2014, 7 (01) : 19 - 28
  • [35] PILOT-STUDY OF INTERLEUKIN-2 AND LYMPHOKINE-ACTIVATED KILLER-CELLS COMBINED WITH IMMUNOMODULATORY DOSES OF CHEMOTHERAPY AND SEQUENCED WITH INTERFERON-ALFA-2A IN PATIENTS WITH METASTATIC MELANOMA AND RENAL-CELL CARCINOMA
    SZNOL, M
    CLARK, JW
    SMITH, JW
    STEIS, RG
    URBA, WJ
    RUBINSTEIN, LV
    VANDERMOLEN, LA
    JANIK, J
    SHARFMAN, WH
    FENTON, RG
    CREEKMORE, SP
    KREMERS, P
    CONLON, K
    HURSEY, J
    BEVERIDGE, J
    LONGO, DL
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1992, 84 (12) : 929 - 937
  • [36] Effects of interleukin-6 inhibition with ziltivekimab in patients at high risk of atherosclerotic events in Japan: results from the phase 2 RESCUE-2 trial
    Wada, Y.
    Jensen, C.
    Meyer, S.
    Yamamoto, Y.
    Honda, H.
    EUROPEAN HEART JOURNAL, 2022, 43 : 2618 - 2618
  • [37] Beneficial in-vitro effects of interleukin-2, interleukin-12, and their combination on functional and receptor characteristics of natural killer cells in metastatic melanoma patients with normal serum lactate dehydrogenase levels
    Martinovic, Katarina M. Mirjacic
    Babovic, Nada Lj.
    Dzodic, Radan R.
    Jurisic, Vladimir B.
    Ninkovic, Aleksandra Z.
    Konjevic, Gordana M.
    MELANOMA RESEARCH, 2016, 26 (06) : 551 - 564
  • [38] Immune effects of escalating doses of granulocyte-macrophage colony-stimulating factor added to a fixed, low-dose, inpatient interleukin-2 regimen: A randomized phase I trial in patients with metastatic melanoma and renal cell carcinoma
    Smith, JW
    Kurt, RA
    Baher, AG
    Denman, S
    Justice, L
    Doran, T
    Gilbert, T
    Alvord, WG
    Urba, WJ
    JOURNAL OF IMMUNOTHERAPY, 2003, 26 (02): : 130 - 138
  • [39] Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma
    Ribas, Antoni
    Kirkwood, John M.
    Atkins, Michael B.
    Whiteside, Theresa L.
    Gooding, William
    Kovar, Andreas
    Gillies, Stephen D.
    Kashala, Oscar
    Morse, Michael A.
    JOURNAL OF TRANSLATIONAL MEDICINE, 2009, 7
  • [40] Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma
    Antoni Ribas
    John M Kirkwood
    Michael B Atkins
    Theresa L Whiteside
    William Gooding
    Andreas Kovar
    Stephen D Gillies
    Oscar Kashala
    Michael A Morse
    Journal of Translational Medicine, 7
12345